FSA Advisors
RPRX icon

FSA Advisors’s Royalty Pharma RPRX Stock Holding History

FSA Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$222K Buy
+3,800
New +$224K 0.1% 249

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

FSA Advisors's RPRX Position: Q3 2026 in Review

FSA Advisors opened a new position in Royalty Pharma (RPRX) in Q3 2026: 3,800 shares worth $222K. The stake represents 0.1% of the portfolio and ranks #249 among its holdings.

393 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • FSA Advisors held 3,800 shares of Royalty Pharma worth $222K as of Q3 2026.
  • Royalty Pharma was a new FSA Advisors position in Q3 2026.
  • Royalty Pharma made up 0.1% of FSA Advisors's portfolio in Q3 2026, its #249 holding.
  • 393 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on FSA Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.